Skip to content

For in vitro research use only. Not for human or animal consumption.

VaultLabs logo
Research use only24h dispatchLot-tracked COA

VaultLabs UAE

CJC-1295 / Ipamorelin for UAE laboratories

The catalogue line is CJC-1295 (no DAC) 5mg + Ipamorelin 5mg: two sequences co-lyophilised in one sealed vial, ordered as one SKU and documented as one unit. Two details on that name do procurement work — the no-DAC designation, and the fact that this blend lot is not a substitute for a single-sequence certificate. Standalone Ipamorelin 5mg is a separate SKU. This page covers what the vial contains, what a two-component certificate has to show, and how the line should be recorded in inventory. Identity data sits on the CJC-1295 / Ipamorelin monograph. For in vitro laboratory research only.

Featured materials

In the catalogue

Janoshik verified

CJC-1295 (NO DAC) 5MG + IPAMORELIN 5MG

Sample on the report: CJC (no DAC) & Ipamorelin 10mg. Ipamorelin 4.83 mg. CJC-1295 (mod GRF 1-29) 4.68 mg. Testing ordered 26 September 2026. Sample received 7 October 2026. Analysis conducted 8 October 2026. Client: VaultLabs UAE. This blend report does not state a purity percentage.

Task
238930
Batch
Oct 26
Laboratory
Janoshik Analytical
Unique key
9426E7TG8A6X

What the no-DAC designation changes for ordering

CJC-1295 circulates in the literature in two forms: with a drug affinity complex and without it. The VaultLabs line carries the no-DAC form, and the two are not interchangeable analytical targets. A requisition that reads CJC-1295 5mg without the qualifier is under-specified, and the resulting mismatch surfaces late — usually when a certificate is compared against a method written for the other form.

The Ipamorelin component is a separate pentapeptide sequence in the same vial. If a protocol needs a certificate describing only Ipamorelin, use standalone Ipamorelin 5mg rather than this blend. CJC-1295 is still not stocked as a single-sequence SKU. The blend specification reference and the single-component comparison cover that decision.

Reading a certificate that has to describe two components

A single headline purity percentage cannot characterise a two-component fill, and a receiving officer who accepts one has not established much. The useful question is whether both named sequences are separately identifiable on the record, and whether the analysis states which method produced that identification. The COA interpretation guide covers how blend records differ from single-substance records.

Per-lot certificates are published to batch verification once uploaded, and the product COA index lists what exists for this line. Certificates never cross lines: a record for this blend cannot release any other SKU, and no single-sequence record can release this one. If a lot is not yet published, raise a documentation request with the lot and order reference.

Inventory notation that survives an audit

Blends fail audits through naming, not through chemistry. Record the full catalogue string — both components, both masses, the no-DAC qualifier — in the inventory row rather than an abbreviation such as CJC/Ipa 5mg, which loses the qualifier and hides the second component from anyone reading the record a year later.

Keep this line on its own row rather than under a growth-axis grouping shared with Tesamorelin 5mg or IGF-1 LR3 100mcg. Those are separate sequences with separate lots and separate certificates; grouping them for convenience is how a substitution passes unnoticed. The CJC-1295 and tesamorelin comparison sets out the catalogue distinction.

Storage, dispatch and scope

Sealed vials are held cold and protected from light and moisture, per the printed label and lot record. Dispatch covers the seven emirates and pricing is in AED at checkout; log lot and time of receipt and move the parcel into cold storage before closing the paperwork. Storage policy guidance is in the research peptide storage guide, and after acceptance the calculator handles mass-and-volume arithmetic your procedure already fixed.

This material is supplied for in vitro laboratory research only. VaultLabs makes no statements about hormonal, physiological or performance outcomes, supplies nothing for human or animal use, personal use or medical application, and provides no administration or preparation guidance for living systems.

Frequently asked questions

Two sequences co-lyophilised in one sealed unit: the no-DAC form of CJC-1295 at a nominal 5 mg alongside Ipamorelin at a nominal 5 mg, labelled with the catalogue name and a single lot identifier.

No. Neither sequence is stocked as a standalone line. If your protocol needs a certificate describing one substance, this blend is not the right purchase for it.

Yes. CJC-1295 exists in DAC and no-DAC forms and they are distinct analytical targets. Carry the qualifier through the requisition, the inventory row and the notebook entry.

Both named components identifiable on the record, with the method stated, rather than one aggregate purity figure. A single percentage tells you very little about a two-component fill.

All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use.